NL-OMON56305招募中不适用
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION - GO42144
Genentech Inc. (een lid van de Roche groep)0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically documented advanced or metastatic solid tumor with KRAS G12C
- •mutation • Age > 18 years at time of signing Informed Consent Form • Women
- •of childbearing potential must agree to remain abstinent or use contraception,
- •and agree to refrain from donating eggs during the treatment period and after
- •the final dose of study as specified in the protocol • Men who are not
- •surgically sterile must agree to remain abstinent or use contraception, and
- •agreement to refrain from donating sperm during the treatment period and after
- •the final dose of study treatment as specified in the protocol
排除标准
- •Malabsorption or other condition that interferes with enteral absorption
- •Active brain metastases
- •Clinically significant cardiovascular dysfunction or liver disease
研究者
相似试验
尚未招募
1 期
GO42144CancerPACTR202203779032822Genentech Inc.10
尚未招募
1 期
A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)metastatic castration-resistant prostate cancerCancer - ProstateACTRN12623001072606South Metropolitan Health Service (SMHS)45
进行中（未招募）
1 期
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa using AAV8X-Linked retinitis pigmentosa (XLRP)MedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-003852-60-GBightstaRx Limited63
进行中（未招募）
1 期
Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid TumorsAdvanced solid tumorsMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000137-17-DEBioAtla134
进行中（未招募）
1 期
A Study to Evaluate the clinical activity and safety of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory OsteosarcomaRelapsed or Refractory OsteosarcomaMedDRA version: 20.0Level: HLTClassification code 10039498Term: Bone sarcomasSystem Organ Class: 100000004864EUCTR2021-000021-27-NLK-Group Beta78